Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12658449 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL5476700 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3727 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL6027558 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL2619251 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415923-A1 | RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| US-11813270-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | KNOW BIO, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813270-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | KNOW BIO, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | NORTHWESTERN UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230241037-A1 | CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT | 1GLOBE HEALTH INST NANJING (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20220160736-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW BIO LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220152063-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW BIO LLC (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210315915-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBAVIRIN | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070258946-A1 | Combination Therapy for Treating Hepatitis C Virus Infection | CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT | 2007-11-08 | — | — | US | disclosed |
| US-20070258946-A1 | Combination Therapy for Treating Hepatitis C Virus Infection | CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT | 2007-11-08 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258946-A1 | Combination Therapy for Treating Hepatitis C Virus Infection | IFNAR1, HAVCR2, IFNG | LMNA 4217/4885SMN1; SMN2 4037/4885ALDH1A1 1064/4885 |
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | IMPDH1, IMPDH2, AMPD3 | LMNA 3194/4885SMN1; SMN2 2108/4885ALDH1A1 97/4885 |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | LMNA 594/4885SMN1; SMN2 706/4885ALDH1A1 400/4885 |
| US-20220160736-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | LMNA 2814/4885SMN1; SMN2 1913/4885ALDH1A1 648/4885 |
| US-20220152063-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | LMNA 2814/4885SMN1; SMN2 1913/4885ALDH1A1 648/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | LMNA 3171/4885SMN1; SMN2 813/4885ALDH1A1 4131/4885 |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | LMNA 4303/4885SMN1; SMN2 4531/4885ALDH1A1 1700/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | LMNA 3203/4885SMN1; SMN2 2211/4885ALDH1A1 2406/4885 |
| US-20210315915-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBAVIRIN | EIF2AK2, IFNAR1, SARS1 | LMNA 3580/4885SMN1; SMN2 979/4885ALDH1A1 711/4885 |
| US-20230241037-A1 | CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT | ACE2, ACE, TMPRSS4 | LMNA 3540/4885SMN1; SMN2 2655/4885ALDH1A1 1542/4885 |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | LMNA 1745/4885SMN1; SMN2 1257/4885ALDH1A1 231/4885 |
| US-11813270-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | NOS1, NOS2, NOS3 | LMNA 2814/4885SMN1; SMN2 1913/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.